A review of topotecan in combination chemotherapy for advanced cervical cancer

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 213-218

  Robati, Minoo ^a   Holtz, David ^a   Dunton, Charles J ^a  

^a LANKENAU HOSPITAL   (United States)

Author keywords

Advanced cervical cancer; Combination chemotherapy; Topotecan

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOLACTOL; MITOMYCIN; NAVELBINE; NEDAPLATIN; PACLITAXEL; PEMETREXED; PENTOXIFYLLINE; TIRAPAZAMINE; TOPOTECAN; VINBLASTINE;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER DISEASE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAIN; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SKIN DISEASE; SURVIVAL RATE; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING;

EID: 41549162405     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Abu-Rustum NR, Lee S, Massad LS. 2000. Topotecan for recurrent cervical cancer after platinum-based therapy. Int J Gynecol Cancer, 10:285-8.
2. Bell MC, Davidson SA, Mathis JM. 2001. Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial. Gynecol Oncol, 80:128-31.
3. Belozerov VE, Van Meir EG. 2005. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs, 16:901-9.
4. Berek JS, Hacker NF. 2005. Practical Gynecologic Oncology (4th ed.) US. Philadelphia, PA: Lippincott Williams and Wilkins. p 385-6.
5. Bookman MA, Blessing JA, Hanjani P. 2000. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol, 77:446-9.
6. Brave M, Dagher R, Farrell A, et al. 2006. Topotecan in combination with Cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston park), 20:1401-11.
7. Brewer CA, Blessing JA, Nagourney RA, et al. 2006. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol, 100:385-8.
8. Choi CH, Kim TJ, Lee SJ, et al. 2006. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and Cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer, 16:1157-64.
9. Dunton CJ, King SA, Neufeld J R.N, et al. 2002. Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecol Oncol, 85:185-7.
10. DuPont NC, Monk BJ. 2006. Chemotherapy in the management of cervical carcinoma. Clin Adv Hematol Oncol, 4:279-6.
11. Fiorica JV. 2003. The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol, 90:S16-21.
12. Fiorica J, Holloway R, Ndubisi B, et al. 2002. Phase II trial of topotecan and Cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol, 85:89-94.
13. Hochster H, Leibes L, Spyer J, et al. 1994. Phase I trial of low dose continuous topotecan infusion in patients with cancer; an active and well-tolerated regimen. J Clin Oncoll 12:553-9.
14. Keys HM, Bundy BN, Stehman FB, et al. 1999. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med, 340:1154-61.
15. Ling YH, Donato NJ, Perez-Soler R. 2001. Sensitivity to topoisomerase I inhibitors and Cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME 180 sublines. Cancer Chemother Pharmacol, 47:473-80.
16. Long HJ 3rd, Bundy Bn, Grendys EC JR, et al. 2005. Randomized phase III trial of Cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol, 23:4623-33.
17. Mainwaring PN, Nicolson MC, Hickish T, et al. 1997. Continuous infusional topotecan in advanced breast and non-small cell lung cancer; no evidence of increased efficacy. Br J Cancer, 76:1636-9.
18. Maluf FC, Leiser Al, Aghajanian C, et al. 2006. Phase II study of tirapazamine plus Cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer, 16:1165-71.
19. Manuel RS, Blessing JA, Boike G. 2000. Cisplatin and pentoxiyilline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncolology Group. Gynecol Oncol, 79:64-6.
20. Monk BJ, Huang HQ, Cella D, et al. 2005. Quality of life outcomes from a randomized phase III trial of Cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol, 23:4617-25.
21. Moore DH, Blessing JA, McQuellon RP, et al. 2004. Phase III study of Cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol, 22:3113-9.
22. Morris M, Eifel PJ, Lu J, et al. 1999. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med, 340:1137-43.
23. Muderspach LI, Blessing JA, Levenback C, et al. 2001. phase II study of topotecan in patients with squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Gynecol Oncol, 81:213-1.
24. Muggia FM, Blessing JA, Mc Gehee R, et al. 2004. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecology Oncology Group. Gynecol Oncol, 94:483-7.
25. Noda K, Sasaki H, Yamamoto T, et al. 1996. Phase II trial of topotecan for cervical cancer of uterus (abstract). Proc Am Soc Clin Oncol, 15:280.
26. Ohwada M, Mashida S, Fujiwara H, et al. 2004. Phase II study of combination chemotherapy using irinotecan and nedaplatin for patients with primary advanced or recurrent cervical cancer (abstract). J Clin Oncol, 22:5088.
27. Omura GA, Blessing JA, Vaccarello L. 1997. Randomized trial of Cisplatin versus Cisplatin plus mitolactol versus Cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol, 15:165-71.
28. Peters III WA, Liu PY, Barrett II RJ, et al. 2000. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol, 18: 1606-13.
29. Pohlmann P, Dileone LP, Cancella. Al, et al. 2002. Phase II trial of Cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol, 25:496-501.
30. Randall-Whitis LM, Monk BJ. 2007. Topotecan in the management of cervical cancer. Expert Opin Pharmacother, 8:227-36.
31. Rose PG, Bundy BN, Watkins EB, et al. 1999. Concurrent Cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med, 340:1144-53.
32. Rowinsky EK, Verweij J. 1997. Review of phase I clinical studies with topotecan. Semin Oncol, 24(Suppl 20):S20-3-S20-10.
33. Saslow D, Castle PE, Cox T, et al. 2007. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin, 57:7-28.
34. Serkies K, Jassem J, dziadziusko R. 2006. Chemotherapy with mitomycin C, ifosfamide, and Cisplatin for recurrent or persistent cervical cancer. Int J Gynecol Oncol, 16:115 2-6.
35. Tiersten AD, Selleck MJ, Hershman DL, et al. 2004. Phase II study of topotecan and paclitaxel for persistent, or metastatic cervical cancer. Gynecol Oncol, 92:635-8.
36. van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, et al. 1995. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol, 13:1769-76.
37. Whitney CW, Sause W, Bundy BN, et al. 1999. Randomized comparison of fluorouracil plus Cisplatin versus hydroxyuria as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a GOG and SWOG study. J Clin Oncol, 17:1339-55.
38. Zanetta G, Fei F, Parma G, et al. 1999. Paclitaxel, ifosfamide and Cisplatin (TIP) chemotherapy for recurrent or persistent squamous- cell cervical cancer. Ann Oncol, 10: 1171-4.